Vedana Therapeutics
Next-gen antibody therapies for migraine prevention
- Category
- Other
- Launched
- June 17, 2026
- Stage
- Series A
- Founder
- Anurag Agarwal
- Website
- vedanatx.com
Vedana Therapeutics is developing next generation, long acting biologic medicines for migraine prevention. The company's pipeline focuses on antibody therapies that target PACAP (pituitary adenylate cyclase activating polypeptide) and other CGRP independent signaling pathways, aiming to provide better disease control for patients who do not respond adequately to current CGRP targeted treatments. The therapies are designed for at home injection, offering convenience and potentially improved adherence.
Discovered via